Objectives: The objective of this study was to characterize cefazolin serum pharmacokinetics in children before, during and after cardiopulmonary bypass (CPB), in order to derive an evidence-based dosing regimen.
Introduction
Post-operative infection in cardiac surgical patients is a cause of major morbidity and mortality and has a considerable financial impact. 1, 2 In paediatric cardiac surgery, the rate of surgical site infections (SSI) is sometimes even higher, when compared with adult procedures. 1 One key prevention strategy is the appropriate use of antibiotic prophylaxis. Shah et al. 3 recently showed that failure to administer a correct antibiotic prophylactic dose resulted in a 2-fold increase in the risk of developing an SSI in children undergoing surgery. Moreover, suboptimal prophylactic dosing likely results in the emergence of antimicrobial resistance necessitating later broadspectrum antibiotic treatment. 4 To date, there is no consensus on optimal antibiotic dosing regimens in children undergoing cardiac surgery with cardiopulmonary bypass (CPB) and current recommendations are based on extrapolation from adults. 1 CPB and post-operative renal function changes have been shown to have a major impact on drug disposition. 5, 6 Moreover, maturational changes in drug pharmacokinetics from birth towards adulthood further complicate optimal drug treatment in the paediatric population. 7 The efficacy of b-lactam antibiotics most strongly relates to the time during which the unbound drug concentration (fT) is above the MIC for the pathogen, i.e. fT >MIC . The pharmacokinetic/pharmacodynamic target (i.e. fT >MIC ) index associated with positive clinical outcomes for b-lactams in critically ill patients is an fT >MIC between 50% and 100% of the dosing interval. 8 Although pharmacokinetic/pharmacodynamic targets for surgical antibiotic prophylaxis are not established, the goal should be to achieve blood and tissue concentrations that exceed pathogen MICs for the entire duration of surgery, until a few hours after skin closure. 1 To date, only sparse data on the pharmacokinetics of unbound cefazolin are available in children during CPB with mild to moderate hypothermia (n ¼ 5 patients) and no data are available after paediatric cardiac surgery. 9 Previously, it has been shown that with traditional untested dosing schemes, antibiotic concentrations in children could be severely altered, increasing the risk of treatment failure and antibiotic resistance. 10, 11 The primary aims of this study were: (i) to quantitatively characterize intravenous cefazolin serum pharmacokinetics, protein binding and predictors of interindividual variability in critically ill children before, during and after CPB; (ii) to evaluate the PTA for the current standard dose regimen; and (iii) to assess if further improved evidence-based practical dosing regimens can be developed for this patient population.
Patients and methods

Study design and ethics
A prospective pharmacokinetic study was conducted at Ghent University Hospital, Ghent, Belgium between November 2012 and May 2014. Patients between 1 day and 15 years of age undergoing cardiac surgery with CPB and receiving cefazolin as standard-care surgical antibiotic prophylaxis were eligible. The research was conducted in accordance with the guidelines of the Declaration of Helsinki, approved by the institutional Ethics Committee and registered at Clinicaltrials.gov (NCT02749981). Written informed consent was obtained from the parents or legal representatives and from the patients if older than 12 years.
Drug dosing and administration
Cefazolin (Mylan V R , Hoeilaart, Belgium) was prescribed at a dose of 25 mg/kg body weight (maximum 2000 mg), administered intravenously as a bolus within 1 h before surgical incision, at the start of rewarming on CPB, 8 h after the second dose and 8 h after the third dose, according to current institutional dosing guidelines. Immediately after drug administration, infusion lines were flushed with normal saline with a minimum of twice the dead space volume.
Blood sampling
Serial blood samples (0.5 mL) were obtained before, during and after CPB from an arterial catheter (or from the arterial CPB circuit sampling port if a sample was taken just prior to the second dose).
Drug and biochemical assays
Cefazolin serum total and unbound concentrations were quantified using a validated HPLC-ultraviolet spectrophotometric method. 12 
Pharmacokinetic analysis
Cefazolin pharmacokinetics was evaluated using the non-linear mixed-effects modelling software NONMEM version 7.2 (ICON, Ellicott City, MD, USA). The first-order conditional estimation method with the interaction option was used to estimate pharmacokinetic parameters and variability. The effect of CPB was modelled using a separate on/off compartment. Intercompartmental clearance from this CPB compartment was fixed to the CPB pump flow rate and volume of distribution to the CPB priming volume ( Figure S1 , available as Supplementary data at JAC Online). Clearance and volume parameters were estimated using unbound concentrations. The total cefazolin concentrations (C t ) and unbound concentrations (C u ) were modelled simultaneously and related to each other, taking into account saturable serum protein binding ( Figure S2 ), using the following equation:
where B max is the maximum protein binding (mg/L) and K D is the dissociation constant (mg/L).
Covariate model development
Continuous covariates were evaluated as follows:
where P i represents the individual parameter estimate of the ith subject, P pop represents the population parameter estimate, cov is the covariate of interest and k the exponent, which could be fixed to 1 for a linear function or estimated. Dichotomic covariates were evaluated using the following equation:
where m was estimated for one of the dichotomic covariate values (e.g. males). Body weight was a priori included as covariate using a power function with a fixed exponent of 0.75 on (intercompartmental) clearance parameters and 1 on volume parameters, normalized by the median body weight. 13 The potential impact of remaining clinical covariates was explored by visual inspection of post hoc individual pharmacokinetic parameter estimates and deviations from population-predicted pharmacokinetic parameters versus covariate plots. Only clinically relevant associations were considered: sex, age, renal function, temperature and comedication covariates for clearance and age and sex for volumes of distribution. Total protein and albumin concentrations were tested on maximum binding protein (B max ). Specifically for the impact of age on clearance, we tested a sigmoidal maturation function based on post-menstrual age:
where F mat is the maturation function, PMA is post-menstrual age, Hill is the Hill coefficient and TM 50 is the maturation half-life.
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Model evaluation
The final population pharmacokinetic model was evaluated as follows. A non-parametric bootstrap analysis (n ¼ 1000 samples) was used to assess parameter precision. Adequate description of time course and variability was assessed using a prediction-corrected visual predictive check (pcVPC) stratified for weight (n ¼ 1000 simulations) and by assessment of the normalized prediction distribution error (NPDE) distribution (n ¼ 1000 simulations).
14,15
PTA simulation analysis
Stochastic simulations were performed to simulate unbound cefazolin concentration-time profiles for the study dosing regimen (SDR) and for three alternative dosing regimens (ADR1-ADR3) in 1000 individuals (Table 1) . Dose regimen simulations were conducted, stratified by three body weight groups. The associated median patient-specific covariates and CPB/surgery characteristics for each of these weight groups, as observed in our clinical study, were used ( Table 2 ). In addition to these typical, median values, we also included a number of additional conservative subscenarios. These scenarios consisted of: (i) patients with a smaller drop in renal function [observed 25th percentile instead of the median estimated glomerular filtration rate (eGFR) fractional change from before to during and after CPB];
(ii) patients with a longer CPB and surgical procedure (observed 75th percentile of time to skin incision/CPB duration/time to skin closure); and (iii) a larger drop in serum albumin concentrations (observed 75th percentile of fractional change in albumin from before to during and after CPB). Based on these scenarios, the simulated fT >MIC was calculated for the perioperative period and the period from skin closure to 24 h after skin incision. The target efficacy exposure was defined as 100% fT >MIC during surgery 1 and 50% fT >MIC after surgery. 16 PTA was calculated for MICs between 0.125 and 16 mg/L. A PTA !90% was defined as optimal. 17 To evaluate proposed dosing regimens, an infection with staphylococci and a worst-case MIC breakpoint of 8 mg/L was used. 1, 18 Further detailed description of the methods is available as Supplementary data.
Results
A total of 56 patients were included. Demographic, clinical and treatment characteristics are summarized in Tables 2 and 3 . Patients younger than 2 years (n ¼ 38) accounted for 67.8% of the study population. Some 497 total and 494 unbound cefazolin concentrations were available for pharmacokinetic analysis with all samples having a concentration above the lower limit of quantification (median of 9 samples per patient) (n ¼ 130/129 total/unbound concentrations before, n ¼ 229/228 during and n ¼ 138/ 137 after CPB). The median unbound fraction was 28% (IQR ¼ 23%-36%) and a median unbound fraction difference of 3% was measured in the repeat analysis (IQR ¼ 2%-3%).
A two-compartment model with first-order elimination plus an additional compartment for the effect of CPB best described the data (Figures S1 and S3). Only a slight bias beyond 15 h of treatment was observed in the plot of conditional weighted residuals over time, potentially due to the sparse nature of the data in this time period. The equations, population pharmacokinetic parameter estimates and their precision are summarized in Table 4 . All structural model parameters were estimated with adequate precision (relative standard error <15%) and adequate precision was further confirmed with the bootstrap analysis. Between-subject variability (BSV) was estimated for clearance, volume parameters and the serum protein-binding dissociation constant. A proportional error model was used to describe residual variability for both the total and unbound concentrations. A more parsimonious covariate model for clearance incorporating weight and GFR performed better compared with a model incorporating weight and an age-based maturation function, with one extra parameter to be estimated (see the Patients and methods section). It had a lower BSV [coefficient of variation (CV) 33% versus 37% on terminal clearance parameter and improved precision on estimated parameters]. Subsequently the GFR model was chosen as the final model. Albumin was implemented as a covariate to describe saturable protein binding. No other collected clinical variables were selected for further statistical covariate testing, based on changes in objective function value and/or visual inspection of the covariate plots and clinical plausibility.
The pcVPC plots are presented in Figure S4 ; the 5th, 50th and 95th percentiles of the predicted concentrations closely follow the percentiles of the observed data, suggesting a good model fit in both cases. The NPDE mean and variance were not significantly different from 0 and 1, respectively (P > 0.1) (data not shown).
PTA analyses for different dosing scenarios in patients with median patient characteristics (see Tables 1 and 2 ) are presented in Figure 1 (during surgery) and Figure 2 (after surgery). PTA for the SDR was between 62% and 70% during surgery and between 89% and 98% after surgery.
Also, the impact on PTA of a longer procedure duration (75th percentile of time to skin incision/CPB duration/time to skin closure), preserved renal function (25th percentile of eGFR fractional change from before to during and after CPB) and drop in albumin concentration during and after CPB (75th percentile of albumin fractional change from before to during and after CPB) are illustrated. Prolonged surgery had a significant negative effect on PTA during surgery (maximum drop of 19%) ( Figure 1) ; the effect of a Paediatric cefazolin pharmacokinetics during cardiopulmonary bypass JAC preserved renal function was smaller (maximum drop of 10%) and mainly after surgery (Figure 2 ). Changes in albumin concentration did not show any effect on PTA. The probability of achieving the target pharmacokinetic/pharmacodynamic index both peri-and post-operatively in conservative patient scenarios (75th percentiles on CPB and surgery duration combined with a 25th percentile on fractional eGFR change) are presented in Figure 3 . PTA with the SDR was within the range of 40%-54%, whilst the ADR3 dosing regimen (Table 1) provided the most optimal PTA between 88% and 99%.
Discussion
To the best of our knowledge, this is the first population pharmacokinetic model describing the serum pharmacokinetics and protein binding of cefazolin in a large cohort of children before, during and after CPB. The developed population pharmacokinetic model was based on rich data from a relevant cohort of infants and children (n ¼ 56 patients). Patients were recruited over a full paediatric age range (6 days to 15 years) and both total and unbound cefazolin concentrations were measured, using an informative blood sampling schedule that was not restricted to the intraoperative period.
We identified an increase in the volume of distribution during CPB, as observed by a limited drop in serum antibiotic concentrations, which is consistent with previous reports on antibiotic pharmacokinetics in children on CPB. 19, 20 It is known that the fairly large ratio of priming volume to the child's circulating blood volume can have an impact on the volume of distribution of hydrophilic antibiotics (e.g. cefazolin) when initiating CPB. 5 To account for this change, a separate CPB compartment was modelled, as previously suggested by Eaton et al. 21 ( Figure S1 ). The volume of distribution of the CPB compartment was estimated to be equal to the priming volume and may suggest that there was little or no adsorption of drug to the polymeric components of the circuit. This is in contrast to earlier in vitro findings of moderate adhesion of cefazolin to paediatric extracorporeal membrane oxygenation (ECMO) circuits. 22 Potential reasons include: (i) absence of a relevant effect due to shorter antibiotic-circuit contact times when compared with ECMO; and (ii) our data were too sparse to identify such a parameter.
We were able to quantify concentration-dependent (saturable) cefazolin serum protein binding, with serum albumin concentration as a covariate on maximum protein-binding capacity in our paediatric population (Equation 1). This is in agreement with previous studies in neonates and adults. [23] [24] [25] Following initiation of CPB, protein binding decreased significantly (P ¼ 0.02) (median ratio unbound According to the modified Schwartz formula. A covariate model on unbound clearance including renal function (as estimated by eGFR) was finally chosen, which is in line with previously published adult pharmacokinetic studies. [26] [27] [28] [29] [30] It performed better than a model including a sigmoidal maturation function on clearance, a method that is commonly used in paediatric population pharmacokinetic modelling. In our opinion, the maturation model would mainly reflect maturation on renal clearance and would be more applicable to a stable patient population, whereas our eGFR model is a more precise and direct measure of renal maturation and disease-driven alterations of renal function in a population with rapidly changing renal function. This is also in agreement with Illamola et al., 31 who compared renal function and age as predictors of amikacin clearance in neonates and showed that creatinine clearance predicted more BSV.
Worsening renal function during and immediately after CPB is common 32, 33 and leads to decreased renal drug elimination. 6 In our patient population, eGFR decreased by a median of 24% during CPB (IQR ¼ 17%-38%), after which it further decreased during the first post-operative hours by a median of 10% (IQR ¼ 0.5%-15%). The reduced serum clearance of cefazolin resulted in more unbound drug being available for redistribution into tissues and the CPB circuit. A similar trend of reduced plasma clearance was previously observed for cefazolin and other renally cleared antibiotics in children during and after CPB. 19, 20 Paediatric cefazolin pharmacokinetics during cardiopulmonary bypass
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In children undergoing CPB, only one small study (n ¼ 12 patients weighing <10 kg) on plasma unbound cefazolin pharmacokinetics has been published. 9 Given the differences in weight range, priming solution volume and content, CPB circuit material, CPB procedure (including hypothermia and pH management) and pharmacokinetic analysis, no valid comparisons of pharmacokinetic parameters between these studies can be made.
With regard to the potential toxicity of our optimized dosing regimens, it should be noted that we specifically chose not to evaluate doses greater than that currently recommended for children (50 mg/kg given as a bolus infusion), to avoid potential safety risks related to higher peak concentrations. 34 Dosing regimens with prolonged infusion times were not tested as they were regarded as impractical in the operating theatre setting. 35 The first alternative dose scenario (ADR1) included the same dosing times as the current paediatric and adult hospital dosing guideline; two alternatives (ADR2 and ADR3) included a supplemental dose at the onset of CPB. The rationale for this timing was 2-fold: from a pharmacokinetic point of view, the start of CPB results in an increase in the distribution volume, leading to an immediate drop in antibiotic concentrations; from a more practical point of view, selecting a fixed timepoint during surgery might also reduce the risk of simply forgetting this extra dose (Table 2) .
Optimal targets for surgical prophylaxis with b-lactam antibiotics are currently unknown. 1 Because only a few surgical patients develop a wound infection, we used the conservative pharmacokinetic/pharmacodynamic target indices for antibiotic treatment, given the immature immune response in younger children, the knowledge that CPB may contribute to immunoparesis and the broad therapeutic range of b-lactam antibiotics. 36, 37 Due to the (Tables 1 and 3 ). Impact on PTA of a minor drop in eGFR (25th percentile) during and after CPB, a longer CPB/surgery duration (75th percentile) or a larger drop in albumin concentration (ALB) during and after CPB (75th percentile) are also shown. Target was defined as 100% of time above MIC.
higher chance of microbial contamination during surgery, a more conservative target (100% fT >MIC ) was chosen for the perioperative period, compared with the immediate post-operative period (50% fT >MIC ). Target attainment was evaluated within a 24 h window after skin incision, as longer post-operative antibiotic courses do not modify the SSI risk. Our analysis challenges the current dosing regimen; for a typical (median) patient population and an MIC of 8 mg/L for staphylococcal infections, the PTA was between 62% and 70% during surgery and between 89% and 98% after surgery (Figures 1 and 2) .
The simulation studies also revealed that it was primarily the duration of surgical (CPB) procedure that reduced the likelihood of achieving optimal cefazolin exposure during surgery (Figure 1 ). This is in accordance with previously reported findings in adults. 38 In this context, interestingly, various studies identified operative and CPB duration as an independent risk factor for SSI after paediatric cardiac surgery. [39] [40] [41] [42] None of these studies measured antibiotic concentrations. A potential relationship between subtherapeutic antibiotic prophylaxis and SSI was, however, confirmed in two studies in adults undergoing cardiac surgery. 43, 44 Although the present study was not powered to estimate an accurate incidence, one patient developed an SSI, which is within the reported range of 1.7-15 SSI per 100 cases. 9 Deep sternal wound infections are serious complications leading to higher morbidity and mortality and maximal precautions should be taken to avoid them.
Renal function, as estimated by the eGFR, also had a significant influence on PTA, mainly in the post-operative period (Figure 2) . These results are also in agreement with previously published data (Tables 1 and 3 ). Impact on PTA of a minor drop in eGFR (25th percentile) during and after CPB, a longer CPB/surgery duration (75th percentile) or a larger drop in albumin concentration (ALB) during and after CPB (75th percentile) are also shown. Target was defined as 50% of time above MIC.
Paediatric cefazolin pharmacokinetics during cardiopulmonary bypass JAC in adults undergoing cardiac surgery. 27 Although albumin concentration was identified as a covariate on protein binding and protein binding slightly decreased on initiation of CPB, varying albumin concentrations had a negligible impact on PTA.
For final dose selection, the PTA in both the peri-and postoperative period was evaluated for patients with prolonged surgery combined with a minor drop in renal function, as the risk of underdosing was considered of greater importance than potential overdosing with a compound like cefazolin, which has relatively low toxicity. In those scenarios, the combined PTA for the current dosing guideline was even lower (between 40% and 54% for an MIC value of 8 mg/L) (Figure 3 ), thereby potentially leading to subtherapeutic treatment. Only the ADR3 with a higher initial dose (40 mg/kg) at induction and a supplemental dose at start of CPB (20 mg/kg) was deemed appropriate. One recent study investigating tissue cefazolin concentrations in infants (n ¼ 12) undergoing CPB also suggested the use of such supplemental dose(s) as potential dose optimization, although without distinct evaluation. 9 Current international dosing guidelines on antibiotic prophylaxis for adults and children aged >1 year recommend a single pre-incision dose (25-50 mg/kg) and a supplemental redosing interval of 4 h (i.e. two times the cefazolin half-life in adults) during prolonged surgery (or whenever there is extensive blood loss). According to this dosing scenario, and assuming that the half-life in children is equal to that in adults, only one patient in our study population would have been redosed during surgery. Evidently, this dosing regimen would result in an even lower PTA than the current SDR with fixed redosing at the start of rewarming on CPB (PTA between 40% and 54% for conservative patient scenarios).
Tissue concentrations were not measured in our study. However, fairly good tissue penetration was described in a comparable subgroup of infants on CPB and moderate hypothermia (n ¼ 5), with remarkably similar plasma unbound and interstitial tissue concentrations (interstitial fluid to plasma unbound AUC ratio: 0.8-1.3). 9 These tissue penetration characteristics for cefazolin were comparable to what has previously been observed in several adult studies. 29, [45] [46] [47] Moreover, unbound serum concentrations are also informative for antimicrobial efficacy, as blood can bathe the incision site and therefore provide antibiotic distribution at the possible site of infection.
Our analysis is based on data from paediatric patients with mild to moderate hypothermia; therefore, these dose recommendations may not apply to conditions with deep hypothermic circulatory arrest. A !50% lower tissue penetration could be expected in this subpopulation. 9 Using the creatinine-based Schwartz formula to accurately estimate GFR has some limitations, especially in young and critically ill children. 48 However, this is still a well-established, bedside method and has been applied in studies of pharmacokinetics in critically ill children as well as in the pRIFLE criteria for defining acute kidney injury. 49 In conclusion, we demonstrated that the current paediatric dose recommendation of cefazolin in patients may result in subtherapeutic concentrations, especially in those patients with preserved renal function and prolonged cardiac surgery. We provided a rational, model-based dose regimen improvement that increases the PTA in this at-risk subpopulation from 40% to >88% for infections with staphylococci. A prospective, randomized controlled trial evaluating efficacy and safety for the optimized dosing strategy is warranted.
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This work was supported by the Clinical Research Fund Ghent University Hospital, Ghent Belgium (grant number WR/1294/APO/001 to P. A. J. G. Figure 3 . PTA (n ¼ 1000 patients) for cefazolin during and after surgery, according to weight category and dosing scenario (Tables 1 and 3 ). Simulated patient scenarios consisted of a longer CPB/surgery duration (75th percentile) in combination with a minor drop in eGFR (25th percentile) during and after CPB. The combined target was defined as 100% of time above MIC during surgery and 50% of time above MIC after surgery until 24 h after skin incision.
